Infasurf for neonatal RDS   Infasurf for neonatal RDS Infasurf for neonatal RDS Infasurf for neonatal RDS Infasurf for neonatal RDS Infasurf for neonatal RDS
Infasurf for neonatal RDS  
Please select your areas of interest and provide your contact information below:
   Product Information
   General Inquiry
   Contracting
   
* Last Name:
* First Name:
* Affiliation:
* Specialty:
  Address:
  City:
  State:          Zip:
* E-mail:
  Phone:
Yes, I would like to receive future communication
     *= required
  RDS is a lung condition that can occur in prematurely born infants whose lungs have not yet completely developed. These infants lack surfactant, which is a substance necessary for lungs to function normally. INFASURF is closest to natural surfactant, providing maximal adsorption that lowers surface tension and improves lung compliance. INFASURF delivers a rapid and sustained response with the first dose for neonates with RDS.1 Within 1 hour from entry, INFASURF significantly lowered FlO2 and MAP, and significantly decreased RDS severity at 24 hours.1,2 INFASURF offers convenient and flexible dosing and has been used in over 100,000 infants.3

Surfactant replacement therapy with INFASURF
Natural surfactant includes several surfactant proteins (SP): A, B, C, and D. Proteins B and C are important because they enable the surfactant to adhere to alveolar surfaces. Surfactant protein B is a critical protein in surfactant because it's responsible for adsorption of the surfactant to the air-fluid interface, and therefore is necessary for optimal surfactant function.4,5 INFASURF, a sterile, organic extract of calf lung lavage, contains both SP-B and C, with a protein-B level that's closest to that of natural surfactant.

 
  Administration of exogenous surfactants, including INFASURF, often rapidly improve oxygenation and lung compliance. Following INFASURF administration, patients should be monitored so that oxygen and ventilatory support can be modified. During dosing with INFASURF, the most common adverse reactions reported in clinical trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), and ETT reflux (21%). These events were generally transient, and not associated with serious complications. If any of these events occur, administration should be interrupted and the infant's condition stabilized.  

  Privacy Policy | © 2008 Forest Pharmaceuticals, Inc. | Contact Us 		 

  This Web site is intended for US healthcare professionals only. 		 
 
1. Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics. 1997;100:31-38. 2. Data on file, Forest Laboratories, Inc. 3. IMS Health.DDD(TM). September 1999 to December 2000. 4. Mizuno K, Ikegami M, Chen C-M, et al. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res. 1995;37:271-276. 5. Hall SB, Venkitaraman AR, Whitsett JA, et al. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis. 1992;145:24-30.